ArticlePloS one2026
Calcitriol attenuates diethylnitrosamine-induced hepatic fibrosis in rats by reducing oxidative stress and fibrogenic mediators.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D deficiency is associated with poor outcomes and increased mortality in cirrhosis. Calcitriol, the active form of vitamin D3, has antioxidant and hepatoprotective properties; however, its effects on diethylnitrosamine (DEN)-induced liver fibrosis remain unclear. This study investigated the effects of calcitriol on oxidative stress, inflammation, and fibrogenesis in DEN-induced liver fibrosis rat model. Male Sprague-Dawley rats (n = 6/group) were assigned to four groups: control (CON), DEN, DEN + low-dose calcitriol (DEN + LVD3: 5 µg/kg BW), and DEN + high-dose calcitriol (DEN + HVD3: 10 µg/kg BW). Liver fibrosis was induced by weekly DEN injections (70 mg/kg, i.p.) for 8 weeks. Calcitriol was administered twice weekly (i.p.) throughout the experiment. Oxidative stress (hepatic malondialdehyde; MDA), liver injury (serum ALT, AST), hepatic inflammation (NF-κB p65), antioxidant gene expression (SOD-1, GPX-1), and fibrosis markers (TGF-β1, MMP-12, TIMP-1, α-SMA, collagen) were evaluated by biochemical assays, immunohistochemistry, qRT-PCR, western blotting and H&E and Sirius Red staining. Calcitriol significantly attenuated DEN-induced oxidative stress by decreasing hepatic MDA levels in a dose-dependent manner, and lowered serum ALT and AST levels. It partially enhanced hepatic antioxidant defenses by increasing SOD-1 expression toward control levels and upregulating GPX-1 expression. Calcitriol also markedly suppressed NF-κB p65 activation and fibrotic markers (TGF-β1, MMP-12, α-SMA, collagen), which corresponded with improved histopathological fibrosis scores. TIMP1 expression remained unchanged across all groups. Therefore, calcitriol attenuates DEN-induced liver fibrosis by reducing oxidative stress, suppressing inflammatory and fibrogenic signaling, and enhancing antioxidant defenses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.